Mangoceuticals, Inc. (MGRX) stock
MGRXNasdaqServices-Misc Health & Allied Services, NECFiscal year ends December 31
$0.15−0.01 (-8.44%)
Close on Nov 18, 2026Market cap $3.16MP/E –Yield –
Mangoceuticals revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Mangoceuticals's revenue for the twelve months ending Jun 30, 2026 was $315.23K, down 38.9% year over year. For fiscal 2025 it was $456.02K, down 26.0% from the year before.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $456.02K | -26.0% |
| FY2024 | Dec 31, 2024 | $615.87K | -15.8% |
| FY2023 | Dec 31, 2023 | $731.49K | +8083.2% |
| FY2022 | Dec 31, 2022 | $8.94K | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $68.76K | -59.1% |
| Q1 FY2026 | Mar 31, 2026 | $67.86K | -37.9% |
| Q4 FY2025 | Dec 31, 2025 | $94.36K | -10.3% |
| Q3 FY2025 | Sep 30, 2025 | $84.25K | -36.8% |
| Q2 FY2025 | Jun 30, 2025 | $168.11K | +3.0% |
| Q1 FY2025 | Mar 31, 2025 | $109.31K | -48.9% |
| Q4 FY2024 | Dec 31, 2024 | $105.25K | -56.9% |
| Q3 FY2024 | Sep 30, 2024 | $133.37K | -45.6% |
| Q2 FY2024 | Jun 30, 2024 | $163.16K | +15.5% |
| Q1 FY2024 | Mar 31, 2024 | $214.10K | +112.6% |
| Q4 FY2023 | Dec 31, 2023 | $244.37K | – |
| Q3 FY2023 | Sep 30, 2023 | $245.16K | – |
| Q2 FY2023 | Jun 30, 2023 | $141.24K | – |
| Q1 FY2023 | Mar 31, 2023 | $100.72K | – |
See a number that looks wrong?